{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:47:54Z","timestamp":1791960474733,"version":"4.3.4"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2004,11]]},"DOI":"10.1136\/ard.2004.028498","type":"journal-article","created":{"date-parts":[[2004,10,12]],"date-time":"2004-10-12T22:33:44Z","timestamp":1097620424000},"page":"ii79-ii83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"S2","title":["The utility of tumour necrosis factor blockade in orphan diseases"],"prefix":"10.1016","volume":"63","author":[{"given":"E C","family":"Keystone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2004.028498_bib1","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.4049\/jimmunol.152.11.5532","article-title":"RNA expression in salivary gland biopsies of Sjogren's syndrome.","volume":"152","author":"Fox","year":"1994","journal-title":"J Immunol"},{"key":"10.1136\/ard.2004.028498_bib2","first-page":"131","article-title":"Tumor necrosis factor \u03b1 and receptors for it in labial salivary glands in Sjogren's syndrome.","volume":"19","author":"Koski","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2004.028498_bib3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/ard.54.3.209","article-title":"Cytokine and adhesion molecule expression in the minor salivary glands of patients with Sj\u00f6gren's syndrome and chronic sialoadenitis.","volume":"54","author":"Cauli","year":"1994","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2004.028498_bib4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/08916939808996281","article-title":"Differential cytokine mRNA expression in human labial minor salivary glands in primary Sjogrens syndrome.","volume":"28","author":"Sun","year":"1998","journal-title":"Autoimmunity"},{"key":"10.1136\/ard.2004.028498_bib5","first-page":"269","article-title":"Role of cytokines in the destruction of acinar structure in Sjogrens syndrome salivary glands.","volume":"77","author":"Azuma","year":"1997","journal-title":"Lab Invest"},{"key":"10.1136\/ard.2004.028498_bib6","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1172\/JCI113903","article-title":"Interleukin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage.","volume":"83","author":"Moser","year":"1989","journal-title":"J Clin Invest"},{"issue":"suppl 9","key":"10.1136\/ard.2004.028498_bib7","first-page":"S403","article-title":"Treatment with pegylated recombinant methionyl human soluble tumor necrosis-factor with type 1 receptor (PEGSTNF-R1) prevents development of Sjogrens syndrome and diabetes in the NOD mouse model.","volume":"42","author":"Tornwald","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.028498_bib8","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1002\/1529-0131(200110)44:10<2371::AID-ART401>3.0.CO;2-W","article-title":"Infliximab in patients with primary Sjogren's syndrome: a pilot study.","volume":"44","author":"Steinfeld","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.028498_bib9","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","article-title":"Inefficacy of infiximab in primary Sjogren's syndrome: results of the randomized controlled trial of remicade in primary Sjogren's (TRIPPS).","volume":"50","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.028498_bib10","first-page":"96","article-title":"Etanercept in the treatment of patients with primary Sjogren's syndrome: a pilot study.","volume":"31","author":"Zandbelt","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2004.028498_bib11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000070852","article-title":"Successful treatment of dermatomyositis with anti-tumor necrosis factor \u03b1. Preliminary observations.","volume":"50","author":"Hengstman","year":"2003","journal-title":"Eur Neurol"},{"key":"10.1136\/ard.2004.028498_bib12","first-page":"S193","article-title":"Etanercept is effective in the treatment of polymyositis\/dermatomyositis which is refractory to conventional therapy.","volume":"43","author":"Saadeyh","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.028498_bib13","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/rheumatology\/keh079","article-title":"Refractory polymyositis responding to infliximab: extensive follow up.","volume":"43","author":"Labioche","year":"2004","journal-title":"Rheumatology"},{"key":"10.1136\/ard.2004.028498_bib14","first-page":"590","article-title":"Successful use of infiximab in a case of refractory juvenile dermatomyositis.","volume":"44","author":"Nzeussseu","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.028498_bib15","first-page":"MO766","article-title":"Use of etanercept in juvenile dermatomyositis.","volume":"46","author":"Miller","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.028498_bib16","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.4049\/jimmunol.160.7.3602","article-title":"Active Wegener's granulomatosis is associated with HLA-DR4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10.","volume":"160","author":"Ludviksson","year":"1998","journal-title":"J Immunol"},{"key":"10.1136\/ard.2004.028498_bib17","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/ki.1993.98","article-title":"In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis","volume":"43","author":"Noronha","year":"1993","journal-title":"Kidney Int"},{"key":"10.1136\/ard.2004.028498_bib18","first-page":"666","article-title":"Serum concentrations of neopterin, soluble interleukin 2 receptor, and soluble tumor necrosis factor receptor in Wegener's granulomatosis.","volume":"24","author":"Nassonov","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2004.028498_bib19","first-page":"1149","article-title":"Etanercept combined with conventional treatment in WG: A six month open-label trial to evaluate safety.","volume":"41","author":"Bedoos","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.028498_bib20","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/rheumatology\/41.11.1303","article-title":"Effectiveness of TNF alpha blockade with infliximab refractory Wegener's granulomatosis.","volume":"11","author":"Lamprecht","year":"2002","journal-title":"Rheumatology"},{"key":"10.1136\/ard.2004.028498_bib21","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1136\/ard.61.6.559","article-title":"Safety and efficacy of TNF alpha blockade in relapsing vasculitis.","volume":"61","author":"Booth","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2004.028498_bib22","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/rheumatology\/41.10.1126","article-title":"Systemic vasculitides: an open label pilot study on 10 patients.","volume":"41","author":"Bartolucci","year":"2002","journal-title":"Rheumatology"},{"key":"10.1136\/ard.2004.028498_bib23","unstructured":"Gause AM, Arbach O, Reinhold-Keller E, Lamprecht P, Voswinkel J, Gross WL, et al. Induction of remission with infliximab in active generalized Wegener's granulomatosis in effective but complicated by severe infections. Arthritis Rheum, 48:S208abstract 450."},{"key":"10.1136\/ard.2004.028498_bib24","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/01.ASN.0000114554.67106.28","article-title":"Prospective study of TNF alpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis.","volume":"15","author":"Booth","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"suppl 24","key":"10.1136\/ard.2004.028498_bib25","first-page":"S6","article-title":"Beh\u00e7et's disease: an update on the pathogenesis.","volume":"19","author":"Gul","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2004.028498_bib26","first-page":"128","article-title":"Systemic levers of the T cell regulatory cytokines IL-10 and IL-12 in Behcet's disease: soluble TNFR-75 as a biological marker of disease activity.","volume":"24","author":"Turban","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2004.028498_bib27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/09629350220131935","article-title":"Serum levels of TNF\u03b1, SIL-2R, IL-6 and IL-8 are increased and associated elevated lipid peroxidation in patients with Beh\u00e7et's disease","volume":"11","author":"Evereklioglu","year":"2002","journal-title":"Mediators Inflamm"},{"key":"10.1136\/ard.2004.028498_bib28","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000055677","article-title":"Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis.","volume":"33","author":"Santo","year":"2001","journal-title":"Ophthal Res"},{"key":"10.1136\/ard.2004.028498_bib29","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","article-title":"Effect of infliximab on sight threatening panuveitis in Behcet's disease.","volume":"358","author":"Sfikakis","year":"2001","journal-title":"Lancet"},{"key":"10.1136\/ard.2004.028498_bib30","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.11204","article-title":"Treatment with infliximab for a child with Behcet's disease.","volume":"49","author":"Saulsburg","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.028498_bib31","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1053\/gast.2001.22556","article-title":"Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: a case report.","volume":"120","author":"Hassard","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1136\/ard.2004.028498_bib32","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1136\/ard.62.3.280","article-title":"Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behcet's syndrome.","volume":"62","author":"Licata","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2004.028498_bib33","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1136\/ard.61.3.283-a","article-title":"Remission of Behcet's syndrome with TNF alpha blocking treatment.","volume":"61","author":"Rozenbaum","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2004.028498_bib34","first-page":"abstract","article-title":"Etanercept is beneficial in controlling the mucocutaneous lesions of Behcet's syndrome.","volume":"46","author":"Melikogllu","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"suppl 2","key":"10.1136\/ard.2004.028498_bib35","doi-asserted-by":"crossref","first-page":"ii51","DOI":"10.1136\/ard.61.suppl_2.ii51","article-title":"Behcet's disease: a new target for anti-tumour necrosis factor treatment.","volume":"61","author":"Sfikakis","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2004.028498_bib36","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0161-6420(03)00406-8","article-title":"Infliximab in the treatment of refractory posterior uveitis.","volume":"110","author":"Joesph","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1136\/ard.2004.028498_bib37","first-page":"S422","article-title":"A prospective trial of infliximab therapy from patients with refractory uveitis: preliminary results.","volume":"48","author":"Suhler","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.028498_bib38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2474-4-19","article-title":"Remission of Behcet's desease with anti-tumor necrosis factor monoclonal antibody therapy: a case report.","volume":"4","author":"Gulli","year":"2003","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1136\/ard.2004.028498_bib39","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s002960050019","article-title":"Immunolocalisation of tumor necrosis factor and its receptors in temporal arteritis.","volume":"17","author":"Field","year":"1997","journal-title":"Rheumatol Int"},{"key":"10.1136\/ard.2004.028498_bib40","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1002\/1529-0131(200112)44:12<2933::AID-ART482>3.0.CO;2-Y","article-title":"Treatment of longstanding active giant cell arteritis with infliximab: report of four cases.","volume":"44","author":"Cantini","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.028498_bib41","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1136\/ard.62.11.1116","article-title":"Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis.","volume":"62","author":"Andonopoulos","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2004.028498_bib42","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1136\/ard.62.4.373","article-title":"Successful treatment of resistant giant cell arteritis with etanercept.","volume":"62","author":"Tan","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2004.028498_bib43","first-page":"760","article-title":"Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study.","volume":"30","author":"Salvarani","year":"2003","journal-title":"J Rheum"},{"key":"10.1136\/ard.2004.028498_bib44","first-page":"5442","article-title":"Utility of anti-TNF therapy in Takayasu's arteritis.","volume":"48","author":"Hoffman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.028498_bib45","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1078\/0171-2985-00197","article-title":"Treatment of refractory Churg\u2013Strauss Syndrome (CSS) by TNF alpha blockade.","volume":"206","author":"Arbach","year":"2002","journal-title":"Immunobiology"},{"key":"10.1136\/ard.2004.028498_bib46","first-page":"abstract","article-title":"The role of infliximab in a pediatric patient with polyarteritis nodosa.","volume":"48","author":"Whitney-Mahoney","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.028498_bib47","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1165\/ajrcmb\/1.6.439","article-title":"Cellular and molecular aspects of granulomatous inflammation.","volume":"1","author":"Kunkel","year":"1989","journal-title":"Am J Resp Cell Mol Biol"},{"key":"10.1136\/ard.2004.028498_bib48","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1164\/ajrccm.156.5.97-02050","article-title":"Sarcoidosis TNF-alpha release from alveolar macrophages and serum level of IL-2R are prognostic markers.","volume":"156","author":"Ziegenhagen","year":"1997","journal-title":"Am J Resp Crit Care Med"},{"key":"10.1136\/ard.2004.028498_bib49","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1378\/chest.124.1.177","article-title":"Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis.","volume":"124","author":"Utz","year":"2003","journal-title":"Chest"},{"key":"10.1136\/ard.2004.028498_bib50","unstructured":"Baughman RP, Bradley DA, Raymond IO, Lower EE, Kerr MA, Winget DB, et al. Double blind randomized trial of a tumor necrosis factor receptor antagonist (Etanercept) for treatment of chronic ocular sarcoidosis. Presented at the American Thoracic Society 2002; Abstract 917."},{"key":"10.1136\/ard.2004.028498_bib51","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1002\/art.11357","article-title":"Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis.","volume":"44","author":"Ulbricht","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.028498_bib52","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2165\/00063030-200317060-00005","article-title":"Tumor necrosis factor in sarcoidosis and its potential for targeted therapy.","volume":"17","author":"Baughman","year":"2003","journal-title":"BioDrugs"},{"key":"10.1136\/ard.2004.028498_bib53","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1378\/chest.124.5.2028","article-title":"Refractory sarcoidosis responding to infliximab.","volume":"124","author":"Roberts","year":"2003","journal-title":"Chest"},{"key":"10.1136\/ard.2004.028498_bib54","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0140-6736(03)12888-7","article-title":"Sarcoidosis.","volume":"361","author":"Baughmann","year":"2003","journal-title":"Lancet"},{"key":"10.1136\/ard.2004.028498_bib55","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1345\/aph.1C249","article-title":"Infliximab treatment of sarcoidosis.","volume":"37","author":"Serio","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1136\/ard.2004.028498_bib56","doi-asserted-by":"crossref","first-page":"296","DOI":"10.7326\/0003-4819-137-4-200208200-00022","article-title":"Infliximab therapy for complicated sarcoidosis.","volume":"137","author":"O'Connor","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2004.028498_bib57","doi-asserted-by":"crossref","first-page":"296","DOI":"10.7326\/0003-4819-137-4-200208200-00021","article-title":"Infliximab therapy for complicated sarcoidosis.","volume":"137","author":"Cook","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2004.028498_bib58","doi-asserted-by":"crossref","first-page":"27","DOI":"10.7326\/0003-4819-135-1-200107030-00010","article-title":"Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha treatment.","volume":"135","author":"Yee","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2004.028498_bib59","first-page":"70","article-title":"Infliximab for refractory sarcoidosis.","volume":"18","author":"Baughmann","year":"2001","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1136\/ard.2004.028498_bib60","unstructured":"Zein NN, Etanercept Study Group. A phase II randomized double blind, placebo controlled study of Tumor Necrosis Factor antagonist (Etanercept, Enbrel) as an adjuvant to interferon and ribavirin in naive patients with chronic hepatitis. Presented at the American Association for Study of Liver Diseases, 2002, Boston. (Abstract 101808)."},{"key":"10.1136\/ard.2004.028498_bib61","first-page":"107","article-title":"Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B and C.","volume":"31","author":"Oniankitan","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2004.028498_bib62","first-page":"1624","article-title":"Fulminant hepatitis after infliximab in a patient with hepatitis B versus treated for an adult onset stills disease.","volume":"30","author":"Michel","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2004.028498_bib63","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/art.10937","article-title":"Persistent efficacy of tumor necrosis factor alpha blockade therapy in SAPHO.","volume":"48","author":"Olivieri","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.028498_bib64","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1002\/art.10539","article-title":"Sustained response to tumor necrosis factor alpha blockade agents in two patients with SAPHO syndrome.","volume":"46","author":"Wagner","year":"2002","journal-title":"Arthritis Rheum"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724498580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724498580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2004.028498","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T14:39:29Z","timestamp":1737556769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724498580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11]]},"references-count":64,"alternative-id":["S0003496724498580"],"URL":"https:\/\/doi.org\/10.1136\/ard.2004.028498","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2004,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The utility of tumour necrosis factor blockade in orphan diseases","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2004.028498","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Copyright 2004 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}